Profile data is unavailable for this security.
About the company
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior CD122 (IL-2 receptor beta) binding without CD25 (IL-2 receptor alpha) affinity, thereby preferentially stimulating cancer-killing effector T cells and NK cells. The Company’s IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials including a Phase IIb trial for recurrent glioblastoma (GBM). The Company’s early-stage Bifunctional SuperKine ImmunoTherapies (BiSKITs) program is designed to enhance the ability of Superkines to treat immunologically cold tumors.
- Revenue in CAD (TTM)0.00
- Net income in CAD-15.42m
- Incorporated2015
- Employees18.00
- LocationMedicenna Therapeutics Corp2 Bloor St W., 7Th FloorTORONTO M4W 3E2CanadaCAN
- Phone+1 (416) 648-5555
- Fax+1 (416) 648-5555
- Websitehttps://www.medicenna.com
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eupraxia Pharmaceuticals Inc | 0.00 | -41.69m | 130.02m | 29.00 | -- | 4.88 | -- | -- | -1.65 | -1.65 | 0.00 | 0.7476 | 0.00 | -- | -- | 0.00 | -122.29 | -127.84 | -185.74 | -935.99 | -- | -- | -- | -- | -- | -85.63 | 0.3455 | -- | -- | -- | -52.63 | -- | -7.69 | -- |
NervGen Pharma Corp | 0.00 | -20.02m | 136.36m | 10.00 | -- | 7.24 | -- | -- | -0.3363 | -0.3363 | 0.00 | 0.2692 | 0.00 | -- | -- | -- | -78.68 | -121.15 | -138.24 | -180.20 | -- | -- | -- | -- | -- | -9.07 | 0.0092 | -- | -- | -- | -8.01 | -- | 2.20 | -- |
Spectral Medical Inc | 1.74m | -17.93m | 136.97m | 29.00 | -- | -- | -- | 78.90 | -0.0643 | -0.0647 | 0.0062 | -0.0721 | 0.2507 | 3.23 | 2.19 | 59,862.07 | -258.89 | -109.65 | -18,581.35 | -175.35 | 37.85 | 63.74 | -1,032.89 | -445.72 | 0.3287 | -2.56 | -- | -- | -4.14 | -16.08 | -104.12 | -- | 31.53 | -- |
Zentek Ltd | 33.61k | -11.98m | 151.23m | 27.00 | -- | 6.73 | -- | 4,499.54 | -0.1197 | -0.1197 | 0.0003 | 0.2228 | 0.0013 | 0.0796 | 0.0876 | 1,244.82 | -44.53 | -41.94 | -48.53 | -44.46 | -573.70 | -- | -35,636.60 | -12,771.31 | 4.27 | -- | 0.0538 | -- | -79.01 | -- | 54.52 | -- | 39.27 | -- |
Cipher Pharmaceuticals Inc | 30.17m | 30.90m | 211.18m | 6.00 | 7.19 | 1.81 | 6.50 | 7.00 | 1.22 | 1.22 | 1.19 | 4.84 | 0.2613 | 1.61 | 3.18 | -- | 26.76 | 21.53 | 29.60 | 27.40 | 81.27 | 83.58 | 102.43 | 57.31 | 7.55 | -- | 0.0038 | 0.00 | 2.36 | -1.44 | -23.48 | 76.18 | -53.51 | -- |
Medicenna Therapeutics Corp | 0.00 | -15.42m | 213.12m | 18.00 | -- | 10.65 | -- | -- | -0.2215 | -0.2215 | 0.00 | 0.2675 | 0.00 | -- | -- | -- | -50.19 | -48.65 | -56.66 | -54.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 55.49 | -- | -- | -- |
OrganiGram Holdings Inc | 152.91m | -289.27m | 241.50m | 987.00 | -- | 0.8133 | -- | 1.58 | -3.57 | -3.57 | 1.80 | 2.88 | 0.3461 | 2.11 | 5.44 | 163,538.00 | -65.48 | -23.49 | -72.67 | -25.39 | -18.34 | -6.87 | -189.18 | -97.37 | 1.98 | -13.02 | 0.0004 | -- | 10.86 | 67.04 | -1,640.54 | -- | -11.62 | -- |
Cardiol Therapeutics Inc | 0.00 | -30.22m | 244.09m | 17.00 | -- | 12.15 | -- | -- | -0.4622 | -0.4622 | 0.00 | 0.2938 | 0.00 | -- | -- | -- | -72.11 | -58.97 | -91.89 | -68.62 | -- | -- | -- | -158,738.10 | -- | -- | 0.0083 | -- | -- | -- | 9.06 | -- | 36.06 | -- |